Yogendra K Gupta
Overview
Explore the profile of Yogendra K Gupta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarangi S, Kumar S, Tripathi M, Kaleekal T, Singh S, Gupta Y
Indian J Pharmacol
. 2022 Mar;
54(1):24-32.
PMID: 35343204
Objectives: Antiepileptic-drug (AED) serum level and inflammatory biomarkers are primarily monitored/assessed during epilepsy treatment for effective seizure control; however, their correlation with seizure recurrence (SR) following AED-tapering has not been...
2.
Sarangi S, Medhi B, Prakash A, Prakash J, Gupta Y
Indian J Pharmacol
. 2021 Jun;
53(2):115-124.
PMID: 34100395
Objectives: The National Formulary of India (NFI), a ready reckoner for medicines among healthcare-professionals aims for promoting rational drug use. This needs periodic update based on evidence-based medicines and suggestions...
3.
Rashid H, Katyal J, Tripathi M, Sood M, Gupta Y
Epilepsy Behav
. 2019 Apr;
95:75-78.
PMID: 31026787
Purpose: The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is an efficient tool for rapid detection of depression, an important comorbid condition in persons with epilepsy (PWE). Since social and...
4.
Sarangi S, Kaur N, Tripathi M, Gupta Y
Neurol India
. 2018 Sep;
66(5):1427-1433.
PMID: 30233018
Context: This study investigated the cost variation among neuropsychiatric drugs prevalent in the Indian market with reference to the National List of Essential Medicines (NLEM, 2015). Aims: To promote the...
5.
Reeta K, Singh D, Gupta Y
Eur J Neurosci
. 2017 Feb;
45(7):987-997.
PMID: 28199036
Alzheimer's disease is a major cause of dementia worldwide. Edaravone, a potent free radical scavenger, is reported to be neuroprotective. The present study was designed to investigate the effect of...
6.
Reeta K, Prabhakar P, Gupta Y
Behav Pharmacol
. 2016 Aug;
27(7):623-32.
PMID: 27561095
Treatment of depression, a common comorbidity in patients with epilepsy, is restricted as certain antidepressants are considered to be proconvulsants. In contrast, anticonvulsant effects have been reported with some antidepressants....
7.
Burt T, Gupta Y, Mehta N, Swamy N, Vishwas , Speers M
J Clin Res Bioeth
. 2015 Jan;
5(5):195.
PMID: 25558428
Like other emerging economies, India's quest for independent, evidence-based, and affordable healthcare has led to robust and promising growth in the clinical research sector, with a compound annual growth rate...
8.
Kumar H, Katyal J, Gupta Y
Biol Trace Elem Res
. 2014 Nov;
163(1-2):208-16.
PMID: 25422092
The role of zinc in seizure models and with antiepileptic drugs sodium valproate (SV) and phenytoin (PHT) was studied using experimental models of seizures in rats. Male Wistar rats, 150-250 ...
9.
Gupta P, Anvikar A, Valecha N, Gupta Y
Malar Res Treat
. 2014 Oct;
2014:837427.
PMID: 25302133
Objective. With large scale rollout of artemisinin based therapy in the National Malaria Control Programme of India, a risk management plan is needed. This depends on adverse drug reaction (ADR)...
10.
Ahmad H, Muiwo P, Ramachandran S, Pandey P, Gupta Y, Kumar L, et al.
FEBS J
. 2014 Jul;
281(17):3904-19.
PMID: 25041463
MicroRNAs control cellular processes by regulating expression of their target genes. Here we report that neuro-epithelial transforming gene 1 (NET1) is a target of tumor suppressor microRNA 22 (miR-22). miR-22...